Cue Biopharma
100 hedge funds and large institutions have $89.2M invested in Cue Biopharma in 2022 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 28 increasing their positions, 28 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
more ownership
Funds ownership: →
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 28
52% less capital invested
Capital invested by funds: $186M → $89.2M (-$96.5M)
Holders
100
Holding in Top 10
1
Calls
$1.11M
Puts
$752K
Top Buyers
| 1 | +$3.32M | |
| 2 | +$2.51M | |
| 3 | +$2.02M | |
| 4 |
BL
Bleichroeder LP
New York
|
+$1.72M |
| 5 |
CC
Carlson Capital
Dallas,
Texas
|
+$1.05M |
Top Sellers
| 1 | -$4.56M | |
| 2 | -$1.44M | |
| 3 | -$1.24M | |
| 4 |
Rafferty Asset Management
New York
|
-$1.1M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$524K |